Call to Action: SARS-CoV-2 and CerebrovAscular DisordErs (CASCADE)

Background and purpose: The novel severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), now named coronavirus disease 2019 (COVID-19), may change the risk of stroke through an enhanced systemic inflammatory response, hypercoagulable state, and endothelial damage in the cerebrovascular system. Moreover, due to the current pandemic, some countries have prioritized health resources towards COVID-19 management, making it more challenging to appropriately care for other potentially disabling and fatal diseases such as stroke. The aim of this study is to identify and describe changes in stroke epidemiological trends before, during, and after the COVID-19 pandemic. Methods: This is an international, multicenter, hospital-based study on stroke incidence and outcomes during the COVID-19 pandemic. We will describe patterns in stroke management, stroke hospitalization rate, and stroke severity, subtype (ischemic/hemorrhagic), and outcomes (including in-hospital mortality) in 2020 during COVID-19 pandemic, comparing them with the corresponding data from 2018 and 2019, and subsequently 2021. We will also use an interrupted time series (ITS) analysis to assess the change in stroke hospitalization rates before, during, and after COVID-19, in each participating center. Conclusion: The proposed study will potentially enable us to better understand the changes in stroke care protocols, differential hospitalization rate, and severity of stroke, as it pertains to the COVID-19 pandemic. Ultimately, this will help guide clinical-based policies surrounding COVID-19 and other similar global pandemics to ensure that management of cerebrovascular comorbidity is appropriately prioritized during the global crisis. It will also guide public health guidelines for at-risk populations to reduce risks of complications from such comorbidities. © 202

Dichlorido[1-(2-methyl-benz-yl)-3-(?6-2,4, 6-trimethyl-benz-yl)-1H-2,3-dihydro-benzimidazol-2-yl-idene]ruthenium(II) dichloro-methane solvate

The title complex, [RuClCl]·CHl is best thought of as containing an octa-hedrally coordinated Ru center with the arene occupying three sites. Two Ru - Cl bonds and one Ru-carbene bond complete the distorted octa-hedron. The carbene portion of the ligand is a benzimidazole ring. This ring is connected to the CCHarene group by a CHbridge. This leads to a system with very little apparent strain. A dichloro-methane solvent mol-ecule completes the crystal structure. Further stabilization is accomplished via C - H?N and C - H?Cl interactions